Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

Publication

Citation
Fairhurst RA, Knoepfel T, Buschmann N, Leblanc C, Mah R, Todorov M, Nimsgern P, Ripoche S, Niklaus M, Warin N, Luu VH, Madoerin M, Wirth J, Graus-Porta D, Weiss A, Kiffe M, Wartmann M, Kinyamu-Akunda J, Sterker D, Stamm C, Adler F, Buhles A, Schadt H, Couttet P, Blank J, Galuba I, Trappe J, Voshol J, Ostermann N, Zou C, Berghausen J, Del Rio Espinola A, Jahnke W, Furet P.: Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. J Med Chem, Volume 63 (21), 2020
Authors
Adler F, Berghausen J, Blank J, Buhles A, Buschmann N, Couttet P, Del Rio Espinola A, Fairhurst RA, Furet P., Galuba I, Graus-Porta D, Jahnke W, Kiffe M, Kinyamu-Akunda J, Knoepfel T, Leblanc C, Luu VH, Madoerin M, Mah R, Niklaus M, Nimsgern P, Ostermann N, Ripoche S, Schadt H, Stamm C, Sterker D, Todorov M, Trappe J, Voshol J, Warin N, Wartmann M, Weiss A, Wirth J, Zou C
Journal
J Med Chem
Year
2020
PubMed
32930584
Machine-readable
REST APIRDF
Palacky University Olomouc

Palacky University Olomouc

Faculty of Science

Department of Physical Chemistry

tř. 17. listopadu 1192/12

771 46 Olomouc

Czech Republic

How to cite?

Juračka J., Šrejber M., Melíková M., Bazgier V., Berka K.: MolMeDB: Molecules on Membranes Database. Database, Volume 2019, 2019, baz078, https://doi.org/10.1093/database/baz078

Follow us

FacebookGithub

Financial Support

  • MolMeDB interoperability with UniProt and SwissLipids – MEYS Czech-Swiss project ELIXIR-IMPACT 8K0208 (2026–2028)
ELIXIRGAČRUP Olomouc
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. | MolMeDB